Mutated U2AF1 is associated with shorter overall survival in MDS and are more likely to transform to AML compared to unmutated U2AF1, suggesting that these patients should undergo a more aggressive treatment plan when this mutation is present [59]. This evidence concerns the gene U2AF1 and myelodysplastic syndrome.